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L-type amino acid transporter 1 (LAT1, SLC7A5) incorporates essential amino acids into cells. Recent
studies have shown that LAT1 is a predominant transporter in various human cancers. However, the
function of LAT1 in thymic carcinoma remains unknown. Here we demonstrate that LAT1 is a critical
transporter for human thymic carcinoma cells. LAT1 was strongly expressed in human thymic carcinoma
tissues. LAT1-speciﬁc inhibitor signiﬁcantly suppressed leucine uptake and growth of Ty82 human
thymic carcinoma cell lines, suggesting that thymic carcinoma takes advantage of LAT1 as a quality
transporter and that LAT1-speciﬁc inhibitor might be clinically beneﬁcial in therapy for thymic
carcinoma.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Thymic carcinomas are rare malignant tumors and are often in
an advanced stage when detected (1). Although chemotherapy is
the mainstay of treatment for thymic carcinomas, patients
frequently show resistance to drugs andmore efﬁcacious treatment
should therefore be established.
LAT1 is a transporter that incorporates essential amino acids
into cells. A unique feature of LAT1 is its extremely high expression
in many human cancers (2,3), whereas only a small amount of LAT1
is detected in a healthy body (4,5), though LAT1 still has a clear role
in normal tissues (6e8).
A LAT1-speciﬁc inhibitor has shown powerful suppressive ef-
fects on many cancer cell lines in vitro and in vivo (9) and is
currently under evaluation in a clinical trial of cancer patients.
Although a wide range of human cancers express LAT1, little is
known about LAT1 in thymic carcinomas. In this study, we inves-
tigated the role of LAT1 in human thymic carcinoma.gy, Chiba University Graduate
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d/4.0/).Ty82 human thymic carcinoma cells were purchased from Jap-
anese Collection of Research Bioresources Cell Bank (Ibaraki). The
cells were cultured in RPMI1640 containing 10% FCS. S2 cells stably
transfected with empty vector, human LAT1 and LAT2 were
described previously (9).
Anti-LAT1 antibody (mouse monoclonal) was kindly provided
by J-Pharma (Tokyo).
Anti-b-actin antibody (clone C4) was purchased from Merck
Millipore (Darmstadt, Germany).
For human tissue staining, surgically excised thymic carcinoma
or thymoma was ﬁxed with formalin, embedded with parafﬁn, and
sliced. The samples were stained with anti-LAT1 antibody and
detected by DAB. The study using human tissue was approved by
Dokkyo Medical University Bioethics Committee.
For western blot analysis, cells were lysed with lysis buffer
(50 mM TriseHCl pH 7.8, 150 mM NaCl, 5 mM EDTA, 1% Tween-20,
10 mM NaF, 1 mM Na3VO4, 3 mM b-glycerophosphate, 5 mM py-
rophosphate, protease inhibitor cocktail (Roche Diagnostics, Basel,
Switzerland)). Protein amount was determined using BCA Protein
Assay Kit (Thermo Fisher Scientiﬁc, Waltham, MA, USA). Western
blot was performed with 3.5 mg of total protein as described pre-
viously (10).
JPH203 was described previously (9).nese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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HBSS containing 1.0 mM [14C]-L-leucine (Moravek, Brea, CA, USA)
and JPH203 at 37 C for 1 min. Uptake was terminated by washing
the cells 3 times with ice cold HBSS. Cells were lysed with 0.1N
NaOH and radioactivity was measured using an LSC-5100 b-scin-
tillation counter (Aloka, Tokyo).
For apoptosis analysis, the cells were stained with annexin V-
FITC and propidium iodide (Medical & Biological Laboratories,
Nagoya) and analyzed by FACS (Becton Dickinson, Franklin Lakes,
New Zealand).
For cell cycle analysis, the cells were initially ﬁxed with 70%
ethanol. After washing the cells with PBS, cells were treated with
RNase A (100 mg/ml) for 30 min at 37 C and further incubated with
2 mg/ml of propidium iodide for 10 min at room temperature. Cell
cycle was analyzed with FACS.
All statistical signiﬁcance was tested with Student's t-test by
comparing JPH203-treated samples with control sample.
To understand the role of LAT1 in thymic carcinoma, we initially
analyzed the expression of LAT1 in human thymic carcinoma tis-
sues. Strong expression of LAT1 was detected in thymic carcinomaFig. 1. LAT1 is a critical transporter of amino acids in thymic carcinoma cells. (A) Tissue stain
Ty82 cells were lysed and LAT1 protein was detected by western blot. As controls, lysates fr
control), and LAT2 (negative control) were also used.(Fig. 1A). On the other hand, LAT1 was hardly found in thymoma
(non-cancer) tissue (Fig. 1A). We next examined LAT1 expression in
Ty82 human thymic carcinoma cell line. Ty82 cells expressed LAT1
at a high level (Fig. 1B). These results indicate that LAT1 expression
is facilitated in human thymic carcinoma cells.
To investigate the functional signiﬁcance of LAT1 in thymic
carcinoma, we assessed the effects of JPH203, a LAT1-speciﬁc in-
hibitor, on the incorporation of amino acids in Ty82 cells. The cells
were incubated with or without JPH203 for 1 min and uptake of
[14C]-labeled L-leucine was analyzed. JPH203 impaired the uptake
of leucine in a dose-dependent manner (Fig. 2). These results
indicate that LAT1 is crucial transporter of amino acids in
Ty82 cells.
We next examined the effect of a LAT1-speciﬁc inhibitor on
growth of Ty82 cells. The cells were cultured in the presence or
absence of JPH203 and the number of cells was counted. The
number of Ty82 cells was clearly reduced by JPH203 (Fig. 3A). To
determine whether the reduction of Ty82 cells by JPH203 arises
from aberrance of the cell cycle or cell death, we ﬁrst analyzed the
survival rate of Ty82 cells treated with JPH203 by annexin V anding of human thymic carcinoma (left) and thymoma (right) with anti-LAT1 antibody. (B)
om S2 cells stably transfected with an empty vector (negative control), LAT1 (positive
Fig. 2. Impaired incorporation of leucine by JPH203. [14C]-L-leucine and JPH203 were
added to Ty82 cells and leucine uptake was analyzed by measuring radioactivity. Data
expressed as the mean ± S.D.
K. Hayashi et al. / Journal of Pharmacological Sciences 132 (2016) 201e204 203propidium iodide (PI) staining. 100 mM JPH203 increased apoptotic
cells (annexin V single positive cells) as well as total dead cells
(annexin V positive cells plus PI positive cells) (Fig. 3B), indicatingFig. 3. Effect of JPH203 on growth of Ty82 cells. (A) Cells were cultured with JPH203 for the i
shown. Data expressed as the mean ± S.D. *P < 0.01. (B) Cells were cultured with JPH203
mean ± S.D. *P < 0.01. **P ¼ 0.011. (C) Cells were cultured with JPH203 for 4 days and the
histogram indicate the percentages of cells in G1, S and G2 phase from the left.that a high concentration of JPH203 induces cell death of Ty-82
that is derived from apoptosis. We also found that JPH203
modestly decreased the population of Ty82 cells in S phase and
increased the population of cells in G1 phase (Fig. 3C), suggesting
that JPH203 prevents progression of the cell cycle from G1 phase
to S phase. These results indicate that JPH203 has an anti-
proliferative effect on Ty-82 cells that is achieved by both cell
death and G1 arrest.
Here we demonstrated that a LAT1-speciﬁc inhibitor has the
ability to exert anticancer effects against thymic carcinoma cells.
Since thymic carcinoma is a relatively infrequent disorder and
there has not been sufﬁcient progress in its therapeutic approach,
the results of our study could offer an additional and effective
treatment option for thymic carcinoma using a LAT1 inhibitor.
However, in our study, high concentration of JPH203 was required
for the sufﬁcient suppression of Ty-82 cells. In experiments with
mice, it appears that the concentration of JPH203 in blood can
exceed 100 mM at the point of administration, but immediately
drops into single digit (9). This result suggests that it is difﬁcult to
maintain a high concentration of JPH203 in vivo. Therefore, it is
recommended combining JPH203 at low concentration with other
anti-cancer drugs to maximize the therapeutic efﬁcacy and
minimize adverse effects when JPH203 is used for clinical
application.ndicated days. The number of the cells was counted, and relative cell number to day 0 is
for 3 days and stained with annexinV and Propium Iodide (PI). Data expressed as the
cell cycle was analyzed by staining the cells with PI. The numbers on the top of the
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